In 2019, Ángela et al. found a new targeted nanomedicine that can deliver a special anti-GSDMB antibody to HER2-positive breast cancer cells, based on hyaluronic acid–biocompatible nanocapsules. Here, ERBB2 is linked to breast carcinoma.